GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Shield Therapeutics STX.L · GBp

Health Care · LSE · 🇬🇧 United Kingdom

Compare

3.15p

-1.56%

Close of 9 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Shield Therapeutics — daily STX

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Shield Therapeutics on TradingView ↗
Market value
£33.6m
Last close × shares
Volume
1.5m
Shares, 9 Nov 2026

About Shield Therapeutics

Its shares trade on LSE under the ticker STX.L. It has been listed since 26 February 2016. In the fiscal year to 31 December 2024, it reported revenue of $32.2m and a net loss of $27.2m. At that date it held total assets of $57.5m and shareholders' equity of −$1.3m.

Shield Therapeutics Plc is a pharmaceutical company. The company is headquartered in Gateshead, Tyne And Wear. The company went IPO on 2016-02-26. The firm's product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed. The company also has a pipeline of over three prescription pharmaceutical assets, including PT20, PT30 and PT40. PT20, which is in Phase II clinical trials, is used as a treatment for hypophosphatemia. PT30, which indicates advanced intravenous (IV) iron formulation, is in pre-clinical stage. Its PT40, which indicates generic IV iron formulation, is in pre-clinical trials. Feraccru, which indicates IDA in chronic kidney disease (CKD) and inflammatory bowel disease (IBD), is in Phase III clinical trials. Its other indications for Feraccru are in Phase II clinical trials.

Figures and description from our data supplier, not checked against the company's own report.

More about Shield Therapeutics →

Latest on Shield Therapeutics

Our reporting

We have not reported on Shield Therapeutics yet.

Next results

29 Apr 2027

Due on 29 Apr 2027.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Shield Therapeutics's ticker?

Shield Therapeutics trades as STX.L on LSE, under ISIN GB00BYV81293.

What was Shield Therapeutics's last closing price?

3.15p on 9 Nov 2026. The figure is in GBp and is never converted.

When does Shield Therapeutics next report results?

Results are expected on 29 Apr 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.